
    
      Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the
      Efficacy and Safety of Ingavirin in the Treatment of Influenza and Other Acute Viral
      Respiratory Infection. Study treatment was 5 days followed by 2 ± 1 days of follow up period.
      Thus, study participation was 7 ± 1 days (8 days max).
    
  